96% of venture capitalists are men1. Women still account for less than 10% of founders for high growth firms2 and earn only 12.9% of computer science degrees3. "She Started It" gives a new face to the image of the tech entrepreneur: a female face.
Join Johnson & Johnson Innovation JLABS and the Innovation Forum for a film screening of "She Started It", a new documentary film that follows five trailblazing young female entrepreneurs through their journeys of entrepreneurship.
The movie screening will be followed by a short panel discussion featuring local influential women in business.
View the trailer for the film here: https://www.youtube.com/watch?v=hcGGrUx666s
2"Sources of Economic Hope" by Kauffman Foundation
3Computing Research Association study
Registration Opens & Welcome
Film Screening of “She Started It”
Q&A with the movie director Nora Poggi
Lisa Chuma educates and empowers female change makers in business how they can successfully secure media interviews for themselves and their businesses. Female change makers who want to be visible, known for something and impact the world.
She recently launch the GET YOURSELF FEATURED LAB with the vision of making it the first point of contact and reference for journalists/editors/bloggers around the world who are looking for influential female change makers in business to write about or interview.
Based in Zug, Switzerland, she was born in Zimbabwe and moved to the UK when she was 16. She graduated from the University of East London.
She arrived in Switzerland in 2011 and within 18 months launched the first and only exhibition for women in Switzerland - the Women’s Expo Switzerland. A platform to support female business owners increase their business visibility by connecting them to new people through face-to-face meetings.
Madiha Derouazi has been working on vector engineering and therapeutic cancer vaccines for over 9 years. She has a strong background in applied molecular and cellular biotechnology, with research interests at the interface of fundamental and translational research. After several years working on recombinant protein production (upstream), she started developing different antigen delivery vectors. In the Laboratory of Tumor Immunology of the University of Geneva, she designed and characterized the CPP-based multi-epitopic cancer vaccine that is currently being progressed by AMAL Therapeutics. Madiha Derouazi holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.
I am an environmental scientist and international development scholar with 19 years of experience in researching sustainable development challenges in the global South. I am interested in how technological innovation can support poverty reduction and sustainable development. I studied at the University of Geneva, the University of Aberdeen (UK) and at the Swiss Federal Institute of Technology (EPFL), conducted research in Burkina Faso, Ghana and Mexico and was based in Bangalore for four years as Executive Director of swissnex India. Currently, I am the Deputy Director of the Cooperation and Development Center at EPFL, in charge of research and education activities and direct the International Conference of the UNESCO Chair in Technologies for Development. I teach Development Engineering at BA/MA level and, in collaboration with my team, have launched a MOOC in disaster risk reduction. My publications include four (co-) edited books, a special issue of the Journal of Sustainable Energy Technologies and Assessments and a number of (co-) authored articles and book chapters. I am a member of the editorial board of the Journal of Development Engineering, a board member of the Conseil Suisse de Recherches Scientifiques en Côte d’Ivoire and the Commission for Research Partnerships with Developing Countries. I am passionate about sustainable development, yoga and hiking in the wilderness.
Nora Poggi is a French journalist/filmmaker directing her debut film on women tech entrepreneurs, SHE STARTED IT, which premieres at the Mill Valley Film Festival in October 2016. She has interviewed key players in Silicon Valley for the past four years for publications including Examiner.com & Usine Nouvelle. She previously worked at French social network Viadeo.com and award-winning production company Lucky Dragon Productions. She is a TEDx speaker and has been featured in Inc, Forbes, Fast Company, Glamour, Huffington Post and many others.
Nora’s speaking experience:
•Women in technology & women entrepreneurs
•Entrepreneurship & Education
•Filmmaking as a startup
Past events include:
•Tedx Women Barcelona, May 2015
•Women’s Leadership Conference, New Haven University, April 2016
•Entrepreneurship at Cornell Celebration, April 2016
•Launch Conference, San Francisco, March, 2016
•NetImpact San Francisco, June 2016
•Square, San Francisco, November 2015
Upcoming events include
Harvard University, Simmons’ Leadership Conference, JLL San Francisco, Indiana University, The Grace Hopper Conference and more.
Anna Quattropani is the Head of Non-Clinical Development and Medicinal Chemistry of Asceneuron. She is responsible for overseeing all non-clinical development activities including medicinal chemistry, chemistry, manufacturing and controls (CMC), ADME, early safety pharmacology and toxicology. She also manages the small molecule intellectual property portfolio of the company. Anna has been a management team member since the inception of Asceneuron with key contributions to the progression of its pipeline from discovery to the clinical phase. She is a Principal Investigator for international research grants awarded by Alzheimer’s Drug Discovery Foundation and Michael J. Fox Foundation.
Anna is an experienced Medicinal Chemist with more than 18 years of experience and a successful track record in the design and optimization of small molecules originating from high throughput screening, fragment discovery and knowledge-based design into drug candidates. During the past ten years, within Serono and then Merck organization, she has been working on a variety of neurodegenerative disease projects, designing and optimizing drug-like small molecules with CNS exposure for multiple sclerosis, Alzheimer’s disease and orphan tauopathies such as progressive supranuclear palsy.
Anna is inventor of several clinical molecules such as the O-GlcNAcase inhibitor ASN120290 for progressive supranuclear palsy and the oxytocin receptor antagonist Nolasiban that has entered Phase 3 clinical studies.
Anna obtained her Ph.D. and M.S. in organic synthesis and organometallic chemistry at University of Geneva, Switzerland. She is the inventor of 34 patents and the author of 20 peer-reviewed publications.
Thursday, September 28th 2017
18:00 – 21:00 (GMT)
Room SV1717, EPFL